000 01407 a2200385 4500
005 20250516090127.0
264 0 _c20120815
008 201208s 0 0 eng d
022 _a1744-8301
024 7 _a10.2217/fon.12.22
_2doi
040 _aNLM
_beng
_cNLM
100 1 _aStevenson, Christina E
245 0 0 _aBevacizumab and breast cancer: what does the future hold?
_h[electronic resource]
260 _bFuture oncology (London, England)
_cApr 2012
300 _a403-14 p.
_bdigital
500 _aPublication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Review
650 0 4 _aAngiogenesis Inhibitors
_xtherapeutic use
650 0 4 _aAnimals
650 0 4 _aAntibodies, Monoclonal, Humanized
_xtherapeutic use
650 0 4 _aAntineoplastic Agents
_xtherapeutic use
650 0 4 _aBevacizumab
650 0 4 _aBreast Neoplasms
_xdrug therapy
650 0 4 _aClinical Trials as Topic
650 0 4 _aDisease Progression
650 0 4 _aFemale
650 0 4 _aHumans
650 0 4 _aNeovascularization, Pathologic
700 1 _aNagahashi, Masayuki
700 1 _aRamachandran, Subramaniam
700 1 _aYamada, Akimitsu
700 1 _aBear, Harry D
700 1 _aTakabe, Kazuaki
773 0 _tFuture oncology (London, England)
_gvol. 8
_gno. 4
_gp. 403-14
856 4 0 _uhttps://doi.org/10.2217/fon.12.22
_zAvailable from publisher's website
999 _c21714776
_d21714776